Marina Pinheiro

List of Publications by Year
in descending order

64 papers	3,105 citations	257101 24 h-index	174990 52 g-index
64 all docs	64 docs citations	64 times ranked	4480 citing authors

#	Article	IF	Citations
1	Hearing loss prevalence and years lived with disability, 1990â€“2019: findings from the Global Burden of Disease Study 2019. Lancet, The, 2021, 397, 996-1009.	6.3	358
2	Five insights from the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1135-1159.	6.3	335
3	Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990â€“2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet, The, 2020, 396, 1250-1284.	6.3	330
4	Global, regional, and national burden of bone fractures in 204 countries and territories, 1990â€“2019: a systematic analysis from the Global Burden of Disease Study 2019. The Lancet Healthy Longevity, 2021, 2, e580-e592.	2.0	277
5	Therapeutic Potential of Epigallocatechin Gallate Nanodelivery Systems. BioMed Research International, 2017, 2017, 1-15.	0.9	112
6	Epigallocatechin Gallate Nanodelivery Systems for Cancer Therapy. Nutrients, 2016, 8, 307.	1.7	105
7	Mucoadhesive chitosan-coated solid lipid nanoparticles for better management of tuberculosis. International Journal of Pharmaceutics, 2018, 536, 478-485.	2.6	101
8	Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer's disease. European Journal of Pharmaceutical Sciences, 2020, 148, 105314.	1.9	95
9	Liposomes as drug delivery systems for the treatment of TB. Nanomedicine, 2011, 6, 1413-1428.	1.7	91
10	The formulation of nanomedicines for treating tuberculosis. Advanced Drug Delivery Reviews, 2016, 102, 102-115.	6.6	83
11	Design of a nanostructured lipid carrier intended to improve the treatment of tuberculosis. Drug Design, Development and Therapy, 2016, Volume 10, 2467-2475.	2.0	77
12	Nanoparticles for Targeted Brain Drug Delivery: What Do We Know?. International Journal of Molecular Sciences, 2021, 22, 11654.	1.8	71
13	The burden of mental disorders, substance use disorders and self-harm among young people in Europe, 1990â€“2019: Findings from the Global Burden of Disease Study 2019. Lancet Regional Health - Europe, The, 2022, 16, 100341.	3.0	70
14	RVG29-Functionalized Lipid Nanoparticles for Quercetin Brain Delivery and Alzheimerâ€™s Disease. Pharmaceutical Research, 2020, 37, 139.	1.7	61
15	Targeted macrophages delivery of rifampicin-loaded lipid nanoparticles to improve tuberculosis treatment. Nanomedicine, 2017, 12, 2721-2736.	1.7	60
16	Mannosylated solid lipid nanoparticles for the selective delivery of rifampicin to macrophages. Artificial Cells, Nanomedicine and Biotechnology, 2018, 46, 653-663.	1.9	59
17	Design, development, and characterization of lipid nanocarriers-based epigallocatechin gallate delivery system for preventive and therapeutic supplementation. Drug Design, Development and Therapy, 2016, Volume 10, 3519-3528.	2.0	47
18	Pseudomonas aeruginosa intensive care unit outbreak: winnowing of transmissions with molecular and genomic typing. Journal of Hospital Infection, 2018, 98, 282-288.	1.4	41

#	Article	IF	Citations
19	Folate-targeted nanostructured lipid carriers for enhanced oral delivery of epigallocatechin-3-gallate. Food Chemistry, 2017, 237, 803-810.	4.2	40
20	Transferrin-functionalized lipid nanoparticles for curcumin brain delivery. Journal of Biotechnology, 2021, 331, 108-117.	1.9	40
21	EGCG Mediated Targeting of Deregulated Signaling Pathways and Non-Coding RNAs in Different Cancers: Focus on JAK/STAT, Wnt/Î²-Catenin, TGF/SMAD, NOTCH, SHH/GLI, and TRAIL Mediated Signaling Pathways. Cancers, 2020, 12, 951.	1.7	36
22	EGCG intestinal absorption and oral bioavailability enhancement using folic acid-functionalized nanostructured lipid carriers. Heliyon, 2019, 5, e02020.	1.4	31
23	The Interleukin-1 (IL-1) Superfamily Cytokines and Their Single Nucleotide Polymorphisms (SNPs). Journal of Immunology Research, 2022, 2022, 1-25.	0.9	31
24	Differential Interactions of Rifabutin with Human and Bacterial Membranes: Implication for Its Therapeutic and Toxic Effects. Journal of Medicinal Chemistry, 2013, 56, 417-426.	2.9	29
25	Design and statistical modeling of mannose-decorated dapsone-containing nanoparticles as a strategy of targeting intestinal M-cells. International Journal of Nanomedicine, 2016, 11, 2601.	3.3	29
26	Nanotechnology Innovations to Enhance the Therapeutic Efficacy of Quercetin. Nanomaterials, 2021, 11, 2658.	1.9	29
27	The Influence of Rifabutin on Human and Bacterial Membrane Models: Implications for Its Mechanism of Action. Journal of Physical Chemistry B, 2013, 117, 6187-6193.	1.2	25
28	Antimicrobial properties of membrane-active dodecapeptides derived from MSI-78. Biochimica Et Biophysica Acta - Biomembranes, 2015, 1848, 1139-1146.	1.4	25
29	Effects of a novel antimycobacterial compound on the biophysical properties of a pulmonary surfactant model membrane. International Journal of Pharmaceutics, 2013, 450, 268-277.	2.6	23
30	Antibiotic interactions using liposomes as model lipid membranes. Chemistry and Physics of Lipids, 2019, 222, 36-46.	1.5	23
31	Current Status of Amino Acid-Based Permeation Enhancers in Transdermal Drug Delivery. Membranes, 2021, 11, 343.	1.4	23
32	In Vitro Assessment of NSAIDs-Membrane Interactions: Significance for Pharmacological Actions. Pharmaceutical Research, 2013, 30, 2097-2107.	1.7	22
33	A 17-mer Membrane-Active MSI-78 Derivative with Improved Selectivity toward Bacterial Cells. Molecular Pharmaceutics, 2015, 12, 2904-2911.	2.3	22
34	Interplay of mycolic acids, antimycobacterial compounds and pulmonary surfactant membrane: A biophysical approach to disease. Biochimica Et Biophysica Acta - Biomembranes, 2013, 1828, 896-905.	1.4	21
35	Effects of novel triple-stage antimalarial ionic liquids on lipid membrane models. Bioorganic and Medicinal Chemistry Letters, 2017, 27, 4190-4193.	1.0	21
36	Mitoxantrone-loaded lipid nanoparticles for breast cancer therapy â€" Quality-by-design approach and efficacy assessment in 2D and 3D in vitro cancer models. International Journal of Pharmaceutics, 2021, 607, 121044.	2.6	20

#	Article	IF	Citations
37	Interactions of isoniazid with membrane models: Implications for drug mechanism of action. Chemistry and Physics of Lipids, 2014, 183, 184-190.	1.5	19
38	Lipid nanoparticles coated with chitosan using a one-step association method to target rifampicin to alveolar macrophages. Carbohydrate Polymers, 2021, 252, 116978.	5.1	19
39	Gold nanostructures as mediators of hyperthermia therapies in breast cancer. Biochemical Pharmacology, 2021, 190, 114639.	2.0	17
40	Drugâ€“membrane interaction studies applied to Nâ€²-acetyl-rifabutin. European Journal of Pharmaceutics and Biopharmaceutics, 2013, 85, 597-603.	2.0	16
41	Tuberculosis Vaccines: An Update of Recent and Ongoing Clinical Trials. Applied Sciences (Switzerland), 2021, 11, 9250.	1.3	16
42	Lipid nanoparticles biocompatibility and cellular uptake in a 3D human lung model. Nanomedicine, 2020, 15, 259-271.	1.7	15
43	Evaluation of the effect of rifampicin on the biophysical properties of the membranes: Significance for therapeutic and side effects. International Journal of Pharmaceutics, 2014, 466, 190-197.	2.6	14
44	Molecular Interaction of Rifabutin on Model Lung Surfactant Monolayers. Journal of Physical Chemistry B, 2012, 116, 11635-11645.	1.2	13
45	Insights about Î±-tocopherol and Trolox interaction with phosphatidylcholine monolayers under peroxidation conditions through Brewster angle microscopy. Colloids and Surfaces B: Biointerfaces, 2013, 111, 626-635.	2.5	12
46	Evaluation of the Structureâ€“Activity Relationship of Rifabutin and Analogs: A Drugâ€“Membrane Study. ChemPhysChem, 2013, 14, 2808-2816.	1.0	11
47	Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy. Pharmaceutics, 2020, 12, 75.	2.0	11
48	The lanthipeptides of Bacillus methylotrophicus and their association with genomic islands. Systematic and Applied Microbiology, 2015, 38, 525-533.	1.2	10
49	Acylation of the S413-PV cell-penetrating peptide as a means of enhancing its capacity to mediate nucleic acid delivery: Relevance of peptide/lipid interactions. Biochimica Et Biophysica Acta - Biomembranes, 2018, 1860, 2619-2634.	1.4	9
50	The burden of injury in Central, Eastern, and Western European sub-region: a systematic analysis from the Global Burden of Disease 2019 Study. Archives of Public Health, 2022, 80, 142.	1.0	9
51	Effect of the alkyl group in the piperazine N-substitution on the therapeutic action of rifamycins: A drug-membrane interaction study. Chemico-Biological Interactions, 2018, 289, 75-80.	1.7	8
52	Epigallocatechin-3-Gallate Delivery in Lipid-Based Nanoparticles: Potentiality and Perspectives for Future Applications in Cancer Chemoprevention and Therapy. Frontiers in Pharmacology, 2022, 13, 809706.	1.6	8
53	Treatment of Francisella infections via PLGA- and lipid-based nanoparticle delivery of antibiotics in a zebrafish model. Diseases of Aquatic Organisms, 2017, 125, 19-29.	0.5	6
54	Interactions of Nâ€²-acetyl-rifabutin and Nâ€²-butanoyl-rifabutin with lipid bilayers: A synchrotron X-ray study. International Journal of Pharmaceutics, 2013, 453, 560-568.	2.6	5

#	Article	IF	Citations
55	Nanomedicine Interventions in Clinical Trials for the Treatment of Metastatic Breast Cancer. Applied Sciences (Switzerland), 2021, 11, 1624.	1.3	5
56	Molecular interactions of rifabutin with membrane under acidic conditions. International Journal of Pharmaceutics, 2015, 479, 63-69.	2.6	4
57	Insights into the Membranolytic Activity of Antimalarial Drug-Cell Penetrating Peptide Conjugates. Membranes, 2021, 11, 4.	1.4	4
58	Oral Administration of Nanoparticles-Based TB Drugs. , 2017, , 307-326.		3
59	Antituberculosis Drug Interactions with Membranes: A Biophysical Approach Applied to Bedaquiline. Membranes, 2019, 9, 141.	1.4	2
60	Special Issue on Drugâ€"Membrane Interactions. Membranes, 2021, 11, 764.	1.4	2
61	Serine-based surfactants as effective antimicrobial agents against multiresistant bacteria. Biochimica Et Biophysica Acta - Biomembranes, 2022, , 183969.	1.4	2
62	New Approaches from Nanomedicine and Pulmonary Drug Delivery for the Treatment of Tuberculosis. , 2018, , 197-234.		1
63	MANAGEMENT OF THE UPPER LIMB ARTERIOVENOUS MALFORMATIONS.. , 2022, 29, 45-51.		1
64	Treatment of Francisella Infections for Aquaculture using PLGA- and Lipid-based 2Nanoparticle Delivery of Antibiotics in a Zebrafish Model. Journal of Aquaculture Research & Development, 2016, 07, .	0.4	0